½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1497570

ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå : ±¸¼º¿ä¼Òº°, Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2024-2030³â)

Automated Compounding Devices Market by Component (ACD Equipment, ACD Software), Product Type (Intravenous Compounding Systems, Oral Compounding Systems, TPN Compounding Systems), Application, End-User - Global Forecast 2024-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 23¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024³â¿¡´Â 25¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 10.52%ÀÇ CAGR·Î 2030³â¿¡´Â 46¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÚµ¿ Á¶Á¦ ±â±â´Â ÀÇ·á ÇöÀå¿¡¼­ Á¶Á¦¿ë ÀǾàÇ°À» ÁغñÇϱâ À§ÇØ ¼³°èµÇ¾ú½À´Ï´Ù. ÀÚµ¿ Á¶Á¦ ±â±â´Â ÀÇ·á ÇöÀå¿¡¼­ Á¶Á¦µÇ´Â ¾à¹°ÀÇ È¥ÇÕ, Èñ¼®, Á¶¸³À» ³ôÀº Á¤¹Ðµµ¿Í ¾ÈÀü¼ºÀ¸·Î ÀÚµ¿È­ÇÏ´Â ÀåºñÀÔ´Ï´Ù. ÀÚµ¿ Á¶Á¦ ±â±â´Â Á¾¾çÇÐ(Ç×¾ÏÁ¦ Á¶Á¦), Á¾ÇÕºñ°æ±¸¿µ¾ç(TPN), ÁýÁß Á¶Á¦ ½Ã¼³¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Â ´ë·® Á¶Á¦ µîÀÇ ºÐ¾ß¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚ¿¡´Â ¹«±Õ ȯ°æ¿¡¼­ È¿À²ÀûÀÌ°í ¾ÈÀüÇÑ ¾à¹° Á¶Á¦°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ÁÖ·Î º´¿ø ¾à±¹, Á¶Á¦ ¾à±¹, ¿Ü·¡ ȯÀÚ ¼­ºñ½º µîÀÌ Æ÷ÇԵ˴ϴÙ. Áõ°¡ÇÏ´Â ¸¸¼º ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ Åõ¾à ¼ö¿äÀÇ Áõ°¡¿Í °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ´õ ¸¹Àº º¹ÇÕÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ȯ°æ¿¡¼­ ¾à±¹ ¾ÈÀü ±âÁØ °³¼±ÀÇ Á߿伺ÀÌ ³ô¾ÆÁö¸é¼­ ÀÚµ¿Á¶Á¦ ÀåºñÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀº ÀÚµ¿È­µÈ Á¶Á¦ ½Ã½ºÅÛÀÇ ¼³Ä¡ ¹× À¯Áöº¸¼ö¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü Àåºñ¸¦ Á¶ÀÛÇÒ ¼÷·ÃµÈ Àü¹®°¡°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ÀÚµ¿ Á¶Á¦ ±â±âÀÇ µµÀÔÀÌ ´õ¿í º¹ÀâÇØÁö°í ÀÖ½À´Ï´Ù. ¼Ò±Ô¸ð Ŭ¸®´ÐºÎÅÍ ´ëÇü º´¿ø±îÁö ´Ù¾çÇÑ »ç¾÷ ±Ô¸ð¿¡ ¸Â´Â È®Àå °¡´ÉÇÑ ±â°è ¸ðµ¨À» ±¸ÃàÇϱâ À§ÇÑ ¿¬±¸¿Í ±â¼ú Çõ½ÅÀÇ ¼ºÀåÀº ½ÃÀå ¼ºÀå ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ³»±¸¼ºÀÌ ¶Ù¾î³ª°í ¼¼Ã´ÀÌ ¿ëÀÌÇÑ Àç·á ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ´Â ¾ö°ÝÇÑ À§»ý ¹× ¹«±Õ ¿ä±¸ »çÇ×À» ÃæÁ·ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 23¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 25¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 46¾ï 9,000¸¸ ´Þ·¯
CAGR(%) 10.52%

Áö¿ªº° ÀλçÀÌÆ®

¾Æ¸Þ¸®Ä«ÀÇ ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀåÀº ¹Ì±¹°ú ij³ª´ÙÀÇ ÀÇ·á ÀÎÇÁ¶ó¿Í ±ÔÁ¦ ȯ°æÀÇ ¿µÇâÀ» Å©°Ô ¹Þ°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ Áõ°¡¿Í ´õºÒ¾î Á¶Á¦ÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀ» ³ôÀ̱â À§ÇØ ÀÇ·á ÀÚµ¿È­°¡ ÃßÁøµÇ¸é¼­ ÀÚµ¿Á¶Á¦ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. À¯·´¿¬ÇÕ(EU)¿¡¼­´Â ¾ö°ÝÇÑ Á¶Á¦ °ü·Ã ±ÔÁ¦, ÀÇ·áºñ Àý°¨¿¡ ´ëÇÑ °ü½É, ¾à±¹ ¹× º´¿øÀÇ ±â¼ú µµÀÔ Áõ°¡°¡ ½ÃÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ µîÀÇ ±¹°¡´Â ÀÇ·áÀÇ Áú°ú ȯÀÚ ¾ÈÀüÀ» Çâ»ó½ÃÅ°±â À§ÇØ ÀÌ·¯ÇÑ ±â±â µµÀÔÀÇ ¼±µÎ¿¡ ¼­ ÀÖÀ¸¸ç, EU´Â ȸ¿ø±¹ °£ ÀǾàÇ° °üÇà Ç¥ÁØÈ­¿¡ °ü½ÉÀ» °®°í ÀÚµ¿ Á¶Á¦ ±â±â µµÀÔÀ» ÃËÁøÇÏ°í ±¹°æÀ» ÃÊ¿ùÇÑ ¿¬±¸ °³¹ß À̴ϼÅƼºê¸¦ ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. Áß±¹, ÀϺ», Àεµ µî ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå¿¡¼­ À¯¸ÁÇÑ ¼ºÀå ±âȸÀÔ´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀå ¿ªÇÐÀº ÀÇ·á ÀÎÇÁ¶óÀÇ ±Þ¼ÓÇÑ ¹ßÀü, ÀÇ·áºñ Áõ°¡, ÀǾàÇ° ¾ÈÀü¿¡ ´ëÇÑ °ü½É Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå¿¡¼­ º¥´õÀÇ Æ÷Áö¼Å´×À» Æò°¡ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º´Â °ø±Þ¾÷ü¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Æò°¡¸¦ Á¦°øÇÏ°í ºñÁî´Ï½º Àü·« ¹× Á¦Ç° ¸¸Á·µµ¿Í °ü·ÃµÈ ÁÖ¿ä ÁöÇ¥¸¦ Á¶»çÇÕ´Ï´Ù. ÀÌ·¯ÇÑ »ó¼¼ÇÑ Æò°¡¸¦ ÅëÇØ »ç¿ëÀÚ´Â ÀÚ½ÅÀÇ ¿ä±¸»çÇ׿¡ µû¶ó Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. Æò°¡¿¡ µû¶ó °ø±Þ¾÷ü´Â ¼º°ø ¼öÁØÀ» ³ªÅ¸³»´Â 4°³ÀÇ »çºÐ¸é, Áï Forefront(F), Pathfinder(P), Niche(N), Vital(V)·Î ºÐ·ùµË´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼®

½ÃÀå Á¡À¯À² ºÐ¼®Àº ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå¿¡¼­ º¥´õÀÇ ÇöȲ¿¡ ´ëÇÑ ÅëÂû·Â ÀÖ°í »ó¼¼ÇÑ Æò°¡¸¦ Á¦°øÇÏ´Â Á¾ÇÕÀûÀÎ µµ±¸ÀÔ´Ï´Ù. °¢ º¥´õÀÇ ±â¿©µµ¸¦ ¸é¹ÐÈ÷ ºñ±³ ¹× ºÐ¼®ÇÏ¿© °¢ º¥´õÀÇ ¼º°ú¿Í ½ÃÀå Á¡À¯À² °æÀï¿¡¼­ Á÷¸éÇÑ °úÁ¦¿¡ ´ëÇÑ ´õ ±íÀº ÀÌÇظ¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¿©µµ¿¡´Â Àüü ¼öÀÍ, °í°´ ±â¹Ý ¹× ±âŸ Áß¿äÇÑ ÁöÇ¥°¡ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, ÀÌ ºÐ¼®Àº Á¶»ç ´ë»ó ±â°£ µ¿¾È °üÂûµÈ ÃàÀû, ´ÜÆíÈ­ ¿ìÀ§, ÇÕº´ÀÇ Æ¯Â¡°ú °°Àº ¿äÀÎÀ» Æ÷ÇÔÇÏ¿© ÀÌ ºÐ¾ßÀÇ °æÀï¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ »ó¼¼ÇÑ Á¤º¸¸¦ ÅëÇØ °ø±Þ¾÷ü´Â ½ÃÀå °æÀï¿¡¼­ ¿ìÀ§¸¦ Á¡Çϱâ À§ÇØ º¸´Ù Çö¸íÇÑ ÀÇ»ç°áÁ¤À» ³»¸®°í È¿°úÀûÀÎ Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå»çÇ×

Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ È®°íÇÑ ¹ßÆÇÀ» ¸¶·ÃÇÏ°íÀÚ ÇÏ´Â Á¶Á÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ±â¾÷Àº ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå¿¡¼­ÀÇ ÇöÀç À§Ä¡¸¦ öÀúÈ÷ Æò°¡ÇÔÀ¸·Î½á Àå±âÀûÀÎ ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ÀÌ Áß¿äÇÑ Æò°¡¿¡´Â Á¶Á÷ÀÇ ÀÚ¿ø, ¿ª·® ¹× Àü¹ÝÀûÀÎ ¼º°ú¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ÇÙ½É °­Á¡°ú °³¼±ÇØ¾ß ÇÒ ¿µ¿ªÀ» ÆľÇÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • ½ÃÀå µð½º·´¼Ç ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ¹ë·ùüÀΰú Áß¿ä °æ·Î ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±â¼ú ºÐ¼®
  • ƯÇ㠺м®
  • ¹«¿ª ºÐ¼®
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ºÐ¼®

Á¦6Àå ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • ACD Àåºñ
  • ACD ¼ÒÇÁÆ®¿þ¾î

Á¦7Àå ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå : Á¦Ç° À¯Çüº°

  • Á¤¸Æ³» Á¶Á¦ ½Ã½ºÅÛ
  • °æ±¸ Á¶Á¦ ½Ã½ºÅÛ
  • TPN Á¶Á¦ ½Ã½ºÅÛ

Á¦8Àå ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå : ¿ëµµº°

  • Ç×»ýÁ¦ Á¶Á¦
  • È­Çпä¹ý Á¶Á¦
  • ¿µ¾ç¼Ò Á¶Á¦

Á¦9Àå ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • º´¿ø
  • ¾à±¹

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå

  • ¾Æ¸£ÇîƼ³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÚµ¿ Á¶Á¦ ±â±â ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍÅ°
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

Á¦14Àå °æÀï Æ÷Æ®Æú¸®¿À

  • ÁÖ¿ä ±â¾÷ °³¿ä
  • ÁÖ¿ä Á¦Ç° Æ÷Æ®Æú¸®¿À
ksm 24.07.01

[181 Pages Report] The Automated Compounding Devices Market size was estimated at USD 2.32 billion in 2023 and expected to reach USD 2.56 billion in 2024, at a CAGR 10.52% to reach USD 4.69 billion by 2030.

The automated compounding devices are designed to prepare medications for dispensing in healthcare settings. These devices automate the process of mixing, diluting, and assembling drugs in various dosages with a high degree of precision and safety. Automated compounding devices are widely used in several areas such as oncology (for chemotherapy drug preparation), total parenteral nutrition (TPN), and high-volume workloads often found in centralized compounding facilities. The end users primarily include hospital pharmacies, compounding pharmacies, and ambulatory services due to their need for efficient and safe preparation of medications in sterile environments. Increased medication needs to manage rising incidences of chronic diseases, along with the rising focus on personalized medicine, fuels demand for more compounded medications. Additionally, the growing importance of improving pharmacological safety standards in healthcare settings incentivizes the adoption of automated compounding devices. High costs associated with the installation and maintenance of automated compounding systems hamper the growth of the automated compounding devices market. The need for skilled professionals to operate these advanced devices further complicates the implementation of automated compounding devices. Growing research and innovation directed toward creating scalable machine models that cater to varying sizes of operations, from small clinics to large hospitals, are expected to create opportunities for market growth. Furthermore, investing in research for materials that are more durable and easy to clean could aid in meeting stringent hygiene and sterility requirements.

KEY MARKET STATISTICS
Base Year [2023] USD 2.32 billion
Estimated Year [2024] USD 2.56 billion
Forecast Year [2030] USD 4.69 billion
CAGR (%) 10.52%

Regional Insights

The market for automated compounding devices in the Americas is highly influenced by the healthcare infrastructure and regulatory environment in the United States and Canada. The increasing prevalence of chronic diseases, coupled with a push towards healthcare automation to enable precision and safety in medication dispensing, fuels the need for automated compounding systems. In the European Union, the market is driven by stringent regulations on medication preparation, a focus on reducing healthcare costs, and increasing adoption of technology in pharmacies and hospitals. Countries such as Germany, France, the UK, and Italy are at the forefront of adopting these devices, aiming to improve the quality of care and patient safety. The EU's interest in standardizing pharmaceutical practices across member states augments the implementation of automated compounding devices and fosters cross-border research and development initiatives. The Asia Pacific region, including countries such as China, Japan, and India, presents a promising growth opportunity for the automated compounding devices market. This region's market dynamics are driven by rapidly developing healthcare infrastructure, increasing healthcare expenditure, and a growing focus on medication safety.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Automated Compounding Devices Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of chronic diseases and surgeries
      • Rising focus on personalized medicines worldwide
      • Growing focus on improving pharmacological safety standards in healthcare settings
    • Market Restraints
      • High cost of development of automated compounding devices
    • Market Opportunities
      • Growing introduction of advanced automated compounding devices
      • Rising inclination towards oral compounding systems
    • Market Challenges
      • Certain technical limitations associated with automated compounding devices
  • Market Segmentation Analysis
    • Product Type: Growing usage of intravenous compounding systems to automate the preparation of parenteral solutions
    • Application: Rising demand for automated compounding devices for nutrient compounding that help in nutrient mixtures
    • End-User: Expanding need for automated compounding devices across hospitals for enhancing the safety of medication preparation
    • Component: Increasing potential of ACD software that plays a pivotal role in the operational efficacy of automated compounding devices
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Automated Compounding Devices Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Automated Compounding Devices Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Introducing Mundus Mini HD by EQUASHIELD: Redefining the Safe Handling of Hazardous Drugs

EQUASHIELD unveiled the Mundus Mini HD, its pioneering automated compounding device tailor-made for processing hazardous drugs with enhanced precision and protection. The introduction of this compact yet potent device signifies a pivotal leap forward for pharmacy compounding automation. The Mundus Mini HD integrates EQUASHIELD's distinguished CSTD to afford the highest degree of safety against contamination, direct exposure, and errors in medication handling with efficiency and accuracy. [Published On: 2023-12-01]

Baxter Introduces ExactaMix Pro, Next-Generation Automated Nutrition Compounder, at ASHP Meeting

Baxter International Inc., renowned for its leadership in nutrition therapy, heralds the upcoming release of its innovative ExactaMix Pro Automated Compounder, anticipated for early 2023 availability to the U.S. market. Exemplifying their commitment to advancing medication preparation, the breakthrough system was showcased at their exhibit during the ASHP 2022 Midyear Clinical Meeting in Las Vegas. [Published On: 2022-12-01]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Automated Compounding Devices Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Automated Compounding Devices Market, highlighting leading vendors and their innovative profiles. These include Amerisource Bergen Corporation, ARxIUM Inc., B. Braun SE, Baxter Healthcare Corporation, Becton, Dickinson and Company, Cantel Medical Corp., CapsulCN International Co., Ltd., Codonics Inc., Fagron N.V., ForHealth Technologies, Fresenius Kabi AG, Grifols International S.A., Health Robotics SRL, Loccioni Group, McKesson Corporation, Meditecno S.r.l., Medtronic PLC, Omnicell, Inc., Quirem Medical B.V., ScriptPro LLC, Talyst LLC, Tecan Group Ltd., Terumo Corporation, and Yuyama Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Automated Compounding Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • ACD Equipment
    • ACD Software
  • Product Type
    • Intravenous Compounding Systems
    • Oral Compounding Systems
    • TPN Compounding Systems
  • Application
    • Antibiotic Compounding
    • Chemotherapy Compounding
    • Nutrient Compounding
  • End-User
    • Ambulatory Surgical Centers
    • Hospitals
    • Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases and surgeries
      • 5.1.1.2. Rising focus on personalized medicines worldwide
      • 5.1.1.3. Growing focus on improving pharmacological safety standards in healthcare settings
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of automated compounding devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing introduction of advanced automated compounding devices
      • 5.1.3.2. Rising inclination towards oral compounding systems
    • 5.1.4. Challenges
      • 5.1.4.1. Certain technical limitations associated with automated compounding devices
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Growing usage of intravenous compounding systems to automate the preparation of parenteral solutions
    • 5.2.2. Application: Rising demand for automated compounding devices for nutrient compounding that help in nutrient mixtures
    • 5.2.3. End-User: Expanding need for automated compounding devices across hospitals for enhancing the safety of medication preparation
    • 5.2.4. Component: Increasing potential of ACD software that plays a pivotal role in the operational efficacy of automated compounding devices
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Automated Compounding Devices Market, by Component

  • 6.1. Introduction
  • 6.2. ACD Equipment
  • 6.3. ACD Software

7. Automated Compounding Devices Market, by Product Type

  • 7.1. Introduction
  • 7.2. Intravenous Compounding Systems
  • 7.3. Oral Compounding Systems
  • 7.4. TPN Compounding Systems

8. Automated Compounding Devices Market, by Application

  • 8.1. Introduction
  • 8.2. Antibiotic Compounding
  • 8.3. Chemotherapy Compounding
  • 8.4. Nutrient Compounding

9. Automated Compounding Devices Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Pharmacies

10. Americas Automated Compounding Devices Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Automated Compounding Devices Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Automated Compounding Devices Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Introducing Mundus Mini HD by EQUASHIELD: Redefining the Safe Handling of Hazardous Drugs
    • 13.3.2. Baxter Introduces ExactaMix Pro, Next-Generation Automated Nutrition Compounder, at ASHP Meeting
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦